ITN type 1 diabetes study identifies subset of patients with strong response to therapy

Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses («responders»), suggesting that these patients could be identified prior to treatment.

Fuente : http://www.eurekalert.org/pub_releases/2013-08/itn…